Emergent gets $1.25 billion booster shot from US government
This article was originally published in Scrip
Executive Summary
Shares of Emergent BioSolutions leaped as high as 14.5%, or $2.24, on word that it snagged a five-year US government contract worth $1.25 billion for 44.75 million doses of the Rockville, Maryland-based biotech's anthrax vaccine BioThrax – the only vaccine licensed by the US FDA to protect against the infection, which is caused by exposure to Bacillus anthracis.